Robust, well characterized preclinical models are essential for the advancement of targeted therapies for colorectal cancer. Colon cancer patient-derived xenograft (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. Crown Bioscience has one of the largest collections of Colorectal cancer PDX models, including subcutaneous and orthotopic models to more closely recapitulate the tumor microenvironment. More
Our Colorectal cancer Patient-derived xenograft models offer the most translational preclinical model for efficacy screening in Colon cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, Patient derived xenograft reflects the heterogeneity and diversity of the human patient population. Colon cancer PDX model will give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® Rectal cancer PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.